Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance

Masa Lasica; Mary A Anderson; Alex Boussioutas; Gareth P Gregory; Nada Hamad; Kate Manos; Penny McKelvie; Michael Ng; Belinda Campbell; Emma Palfreyman; Ross Salvaris; Robert Weinkove; Joel Wight; Stephen Opat; Constantine Tam

doi:10.1111/imj.16390

Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance

Intern Med J. 2024 Jun;54(6):1017-1030. doi: 10.1111/imj.16390.

Authors

Masa Lasica^{1

2}, Mary A Anderson^{3

4}, Alex Boussioutas^{5

6

7

8}, Gareth P Gregory^{9

10}, Nada Hamad¹¹, Kate Manos¹², Penny McKelvie¹³, Michael Ng¹⁴, Belinda Campbell^{15

16

17}, Emma Palfreyman¹⁸, Ross Salvaris^{19

20}, Robert Weinkove^{21

22

23}, Joel Wight^{24

25}, Stephen Opat^{10

26}, Constantine Tam^{27

28}

Affiliations

¹ Department of Clinical Haematology, St Vincent's Hospital, Melbourne, Victoria, Australia.
² The University of Melbourne, Melbourne, Victoria, Australia.
³ Department of Clinical Haematology, Royal Melbourne Hospital and The Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁴ Division of Blood Cells and Blood Cancer, Walter and Eliza Hall Institute, Melbourne, Victoria, Australia.
⁵ Department of Gastroenterology, Alfred Health, Melbourne, Victoria, Australia.
⁶ Monash University, Melbourne, Victoria, Australia.
⁷ The Alfred, Melbourne, Victoria, Australia.
⁸ Familial Cancer Clinic, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁹ Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia.
¹⁰ Monash Haematology, Monash Health, Melbourne, Victoria, Australia.
¹¹ Department of Haematology, St Vincent's Hospital, Sydney, New South Wales, Australia.
¹² Department of Haematology, Flinders Medical Centre, Adelaide, South Australia, Australia.
¹³ Department of Anatomical Pathology, St Vincent's Hospital, Melbourne, Victoria, Australia.
¹⁴ GenesisCare St Vincent's Hospital, Melbourne, Victoria, Australia.
¹⁵ Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
¹⁶ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
¹⁷ Department of Clinical Pathology, University of Melbourne, Melbourne, Victoria, Australia.
¹⁸ Department of Haematology, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
¹⁹ Department of Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
²⁰ School of Medicine, University of Western Australia, Perth, Western Australia, Australia.
²¹ Te Rerenga Ora Blood & Cancer Centre, Te Whatu Ora Health New Zealand Capital, Coast & Hutt Valley, Wellington, New Zealand.
²² Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand.
²³ Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealand.
²⁴ Department of Haematology and Bone Marrow Transplantation, Townsville University Hospital, Townsville, Queensland, Australia.
²⁵ School of Medicine, James Cook University, Townsville, Queensland, Australia.
²⁶ School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia.
²⁷ Haematology Department, Alfred Hospital, Melbourne, Victoria, Australia.
²⁸ Central Clinical School, Monash University, Melbourne, Victoria, Australia.

PMID: 38881453
DOI: 10.1111/imj.16390

Abstract

Marginal zone lymphomas (MZLs) are a rare, indolent group of non-Hodgkin lymphomas with different diagnostic, genetic and clinical features and therapeutic implications. The most common is extranodal MZL of mucosa-associated lymphoid tissue, followed by splenic MZL and nodal MZL. Patients with MZL generally have good outcomes with long survival rates but frequently have a relapsing/remitting course requiring several lines of therapy. The heterogeneous presentation and relapsing course present the clinician with several diagnostic and therapeutic challenges. This position statement presents evidence-based recommendations in the setting of Australia and New Zealand.

Keywords: Australasian Lymphoma Alliance; marginal zone lymphoma; practice statement; treatment.

MeSH terms

Australia
Consensus
Humans
Lymphoma, B-Cell, Marginal Zone* / diagnosis
Lymphoma, B-Cell, Marginal Zone* / therapy
New Zealand